Pharmaceuticals - Union Register


Register of orphan medicinal products


Product information


EU orphan designation number: EU/3/13/1203   
Active ingredient: Ibrutinib
Indication: Treatment of diffuse large B-cell lymphoma
Sponsor: Janssen-Cilag International NV
Turnhoutseweg 30, 2340 Beerse, België

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
15/11/2013 Orphan designation EMA/OD/116/13 (2013)8050 of 13/11/2013